Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alkermes Sells Gainesville GMP Facility to Recro | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alkermes Sells Gainesville GMP Facility to Recro

Streamlines manufacturing ops into Athlone and Wilmington facilities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alkermes plc has entered a definitive agreement to sell its manufacturing facility in Gainesville, GA, along with global rights and royalty revenue associated with Meloxicam IV/IM, to Recro Pharma for an initial cash payment of $50 million, development and commercialization milestones of as much as $120 million and royalties on sales of Meloxicam IV/IM. The transaction, subject to customary terms and conditions, is expected to close in 2Q15.
 
Assets inlcuded in the transaction are: the Gainesville facility; rights to RITALIN LA, FOCALIN XR, VERELAN, ZOHYDRO ER, and BIDIL; and the late-stage, parenteral formulation of Meloxicam IV/IM, a nonsteroidal anti-inflammatory drug ready for Phase III development for the management of moderate-to-severe acute pain, as well as related technology.
 
“We are streamlining Alkermes’ manufacturing operations for our commercial products and late-stage pipeline into our two GMP facilities in Athlone, Ireland, and Wilmington, OH,” said James Frates, chief financial officer of Alkermes. “With this transaction, we are capturing value from non-core assets, as we continue to execute on our strategy and focus on the key driver of our future growth – our late-stage pipeline of innovative medicines for central nervous system diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics